Zymeworks ($ZYME) faces an FDA decision on Aug 25 for Ziihera with strong Phase 3 data and a $250M approval milestone, but the stock has already rallied from $22 to $26+ in early August, raising questions about whether the catalyst is priced in. Key risk: binary outcome with potential 'sell the news' reaction if approval occurs or significant downside if CRL issued.